Targovax: Funding, Investors & Team (Sep 2026)

Targovax AS focuses on creating cancer vaccines through active immunotherapy. Their most promising candidate is TG01, which is currently undergoing a phase I/II clinical trial in pancreatic cancer patients who have undergone surgery. TG01 utilizes peptides that work to stimulate a response from both a helper and cytotoxic T-cell, which can lead to a strong and long-lasting immune response. The Targovax peptides are geared towards inducing RAS mutation specific T-helper cells through the presentation on HLA class II molecules, as well as for natural processing through potential HLA class I epitopes to induce RAS mutation specific cytotoxic T cells. The Th cells are crucial for coordinating immune responses and play a significant role in the immune system's function. The drug candidate has shown promising results in previous trials, including increased survival rates and limited side effects. Targovax AS was founded in 2010 by the inventors of the technology and the Radium Hospital Research Foundation.

Targovax has raised $4.4M across 2 rounds on record. The most recent is an undisclosed round of $3.5M announced in Mar 2023.

Targovax's most recent funding round on record is an undisclosed round of $3.5M, announced in Mar 2023.

FundedIQ lists Gustav Gaudernack (Founder) at Targovax.

Erik Digman Wiklund is listed as CEO at Targovax.

Targovax is based in Oslo, Norway.

Targovax is in the 11-50 employee band.

Targovax's latest round of $3.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.